Roll of Stem Cell Therapy in Osteoarthritis
Osteoarthritis (OA) is by far the most prevalent type of degenerative joint disease. It is a painful, long-lasting disorder that can affect any synovial joint. Over the future decades, diseases would impose a significant socioeconomic burden on society as a result of an ageing population and rising disease prevalence . The fact that there are few OA therapy choices complicates this situation. Since neither pharmacological nor non-operative treatments have shown to be effective in slowing or stopping the progression of disease, treatment is limited to managing aggravating variables over the long term and managing pain. When mechanical deformity is evident, surgical alternatives such as osteotomies are available to improve alignment and reduce the risk of OA; however, these operations are of limited effect once severe degenerative changes have occurred . Despite improvements in these techniques, they cannot be used to treat more severe joint degeneration brought on by OA. The hunt for disease-modifying remedies goes on in the lack of successful tactics.
For degenerative musculoskeletal disorders like OA, mesenchymal stem cells (MSCs) have been recommended as the best restorative cellular treatment. These cells can quickly multiply and differentiate into musculoskeletal lineages like bone and cartilage. They can be found in a range of tissues . A large body of research has also shown that these cells control crucial immunologic processes by modifying the local inflammatory response. Together, these elements lend credence to MSCs' potential to prevent degenerative joint disease. Due to the fact that this cytotype can be found in a wide variety of tissues, research has concentrated on identifying the best source for MSC generation . Thus, MSC-based therapeutic approaches can be employed to treat OA as a standard treatment plan in near future
Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Current Opinion in Rheumatology. 2002 Sep; 14(5):573-7. doi: 10.1097/00002281-200209000-00017
Bert JM and Gasser SI. Approach to the osteoarthritic knee in the aging athlete: debridement to osteotomy. Arthroscopy. 2002 Dec; 18(9 Suppl 2):107-10. doi: 10.1053/jars.2002.36513
Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Research and Therapy. 2007; 9(1):204. doi: 10.1186/ar2116
Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells and Development. 2012 Sep; 21(14):2724-52. doi: 10.1089/scd.2011.0722
How to Cite
Copyright (c) 2022 THE THERAPIST (Journal of Therapies & Rehabilitation Sciences)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments firstname.lastname@example.org